- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT04709900
CT-stress Myocardiale perfusie, fractionele stroomreserve en angiografie bij patiënten met stabiele pijnsyndromen op de borst (DYNAMITE)
DYnamic CT Stress Myocardperfusie, CT Fractional Flow Reserve en coronaire CT-angiografie voor een geoptimaliseerde behandelingsstrategie bij patiënten met stabiele pijnsyndromen op de borst
The purpose of the DYNAMITE trial (Dynamic CT stress myocardial perfusion, CT fractional flow reserve (FFR-CT) and coronary CT angiography for optimized treatment strategy in patients with chest pain syndromes) is to determine the ability of combined anatomical and functional cardiac CT imaging to improve morbidity and mortality in patients with suspected or known ischemic heart disease.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Trial design
The DYNAMITE trial is an investigator-initiated, randomised controlled, open-labelled trial conducted in the Capital Region of Copenhagen, Denmark
The following hypothesis will be tested:
- First primary hypothesis: A treatment strategy guided by combined dynamic CT myocardial stress perfusion, FFR-CT and CT coronary angiography improves clinical outcome compared with a conventional management strategy in patients with chronic chest pain syndromes
- Second primary hypothesis: A treatment strategy guided by combined dynamic CT stress myocardial perfusion, FFR-CT and CT coronary angiography results in improved symptom relief compared with a conventional management strategy in patients with chronic chest pain syndromes
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Klaus F Kofoed, MD
- Telefoonnummer: 004535458569
- E-mail: Klaus.kofoed@regionh.dk
Studie Locaties
-
-
-
Copenhagen, Denemarken, 2100
- Werving
- Department of Cardiology and Radiology, Rigshospitalet, The Heart Center, Capital Region of Copenhagen, University of Copenhagen
-
Contact:
- Klaus F Kofoed, MD, DmSc
- Telefoonnummer: +45 35458569
- E-mail: Klaus.kofoed@regionh.dk
-
Onderonderzoeker:
- Jesper J Linde, MD, Ph.D
-
Onderonderzoeker:
- Lars V Køber, MD,DmSc
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Kind
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
Chest pain in patients with clinically suspected or confirmed ischemic heart disease
-
Clinical indication for non-acute coronary evaluation
-
Status of coronary revascularization
-
With previous coronary revascularization - all patients
-
Without previous coronary revascularization
-
Age≥65 years - all patients with chest pain
-
Age>50 - <65 years - typical angina pectoris and at least one cardiovascular risk factor and/or previous myocardial infarction
- Typical angina requiring all 3 criteria present: a) constrictive discomfort in the front of the chest or in the neck, jaw, shoulder or arm, b) precipitated by physical exertion c) relieved by rest or nitrates within 5 min.
- Cardiovascular risk factors: hypertension, diabetes, hypercholesterolemia, current smoking, family history of ischemic heart disease, previous stroke, peripheral artery disease
-
-
Exclusion Criteria:
- Persistent chest pain and signs of ongoing acute myocardial ischemia requiring acute coronary intervention
- Hospitalization and discharge with the confirmed diagnosis acute coronary syndrome (STEMI or NSTEMI) within the last 6 months
- Severe valvular heart disease as primary diagnosis and/or in potential need of percutaneous or surgical valve treatment
- Known severe heart failure (LVEF less than 35%)
- Language, cultural or mental factors preventing the patient from understanding the informed consent form
- Known atrial fibrillation
- Known renal impairment (estimated Glomerular Filtration Rate below <30 ml/min)
- Known x-ray contrast allergy
- Known intolerance to adenosine infusion
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: Intervention group
CT angiography, FFR-CT and dynamic CT stress myocardial perfusion guided treatment strategy |
The study intervention team consists of a specialist in Cardiac CT imaging, an invasive cardiologist, a thoracic surgeon and a cardiology nurse specialist. Treatment strategy defined by the study team based on CT findings involve referral for percutaneous coronary intervention, Coronary Artery Bypass surgery and/or initiation of optimal medical therapy, in addition to potential supplementary diagnostic procedures. |
|
Geen tussenkomst: Standard care group
Evaluation and treatment strategy according to contemporary clinical practice |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Major Adverse Cardiovascular Events
Tijdsspanne: 3 years
|
cardiovascular death, acute myocardial infarction, stroke or hospitalization for heart failure |
3 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Individual components of the primary endpoint
Tijdsspanne: 3 years
|
cardiovascular death; acute myocardial infarction; stroke or hospitalization for heart failure |
3 years
|
|
Acute myocardial infarction stratified by subtype
Tijdsspanne: 12 months
|
Subtypes of acute myocardial infarction according to Fourth Universal Definition 2018 |
12 months
|
|
Hospitalization due to unstable angina pectoris, bleeding, pacemaker and/or implantable/cardioverter defibrillator implantation, surgical or percutaneous heart valve treatment
Tijdsspanne: 3 years
|
Cardiovascular hospitalizations |
3 years
|
|
All-cause mortality
Tijdsspanne: 3 years
|
All-cause mortality |
3 years
|
|
All-cause mortality
Tijdsspanne: 10 years
|
Long-term registry based all-cause mortality at 10 years |
10 years
|
|
Number and type of diagnostic tests performed
Tijdsspanne: 12 months
|
Cardiac CT, Exercise ECG, perfusion Positron Emission Tomography, perfusion Single-photon emission computed tomography, perfusion magnetic resonance, invasive coronary angiography, invasive fractional flow reserve, intravascular ultrasound, optical coherence tomography |
12 months
|
|
Number of invasive coronary test not leading to coronary revascularization
Tijdsspanne: 12 months
|
number of invasive procedures |
12 months
|
|
Number of coronary revascularization
Tijdsspanne: 3 years
|
Coronary bypass surgery and/or percutaneous coronary intervention |
3 years
|
|
Cumulative iodinated contrast volume
Tijdsspanne: 12 months
|
Cardiac computed tomography, invasive coronary angiography, invasive fractional flow reserve, intravascular ultrasound, invasive optical coherence tomography |
12 months
|
|
Cumulative radiation dose
Tijdsspanne: 12 months
|
Cardiac CT, perfusion Positron Emission Tomography, perfusion Single-photon emission computed tomography, perfusion magnetic resonance, invasive coronary angiography, invasive fractional flow reserve, intravascular ultrasound, optical coherence tomography |
12 months
|
|
Major procedural complications occuring during procedures (invasive, non-invasive or coronary revascularization)
Tijdsspanne: 12 months
|
death, cardiac arrest, cardiac arrhytmia, acute myocardial infarction, stroke, bleeding, unplanned revascularization and any complication requiring and/or prolonging hospitalizaation at least 24 hours |
12 months
|
|
Minor procedural complication specific to type of procedure (invasive, non-invasive or during coronary revascularization)
Tijdsspanne: 12 months
|
Minor procedural complications |
12 months
|
|
Patients diagnosed with non-cardiac disease as likely explanation for symptoms
Tijdsspanne: 12 months
|
non-cardiac diseases causing chest pain |
12 months
|
|
Seattle Angina Questionaire
Tijdsspanne: 3 months and 12 months
|
Seattle Angina Questionaire pre-randomization, 3 months and 12 months after randomization |
3 months and 12 months
|
|
Quality of life by EQ-5D-5L instrument
Tijdsspanne: 3 months and 12 months
|
Quality of life estimated by EQ-5D-5L instrument pre-randomization, 3 months and 12 months after randomization |
3 months and 12 months
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Klaus F Kofoed, MD, Department of Cardiology, Rigshospitalet, University of Copenhagen, Denmark
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Pijn
- Neurologische manifestaties
- Cerebrovasculaire aandoeningen
- Hersenziekten
- Ziekten van het centrale zenuwstelsel
- Ziekten van het zenuwstelsel
- Vaatziekten
- Hartziekten
- Arteriosclerose
- Arteriële occlusieve ziekten
- Hart-en vaatziekte
- Myocardiale ischemie
- Pathologische aandoeningen, tekenen en symptomen
- Tekenen en symptomen
- Hartinfarct
- Hartfalen
- Hart-en vaatziekten
- Coronaire hartziekte
- Pijn op de borst
- Diagnostische technieken en procedures
- Diagnose
- Tomografie
- Diagnostische beeldvorming
- Radiografie
- Afbeelding interpretatie, computerondersteund
- Radiografische beeldverbetering
- Beeldverbetering
- Fotografie
- Tomografie, röntgenfoto
- Tomografie, röntgencomputer
- Multimodale beeldvorming
- Computed Tomography Angiography
Andere studie-ID-nummers
- NNF19OC0057592
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Following publication of the main results of the trial, anonymized data will be made available to other researchers through the Zenodo open data repository.
IPD-tijdsbestek voor delen
Statistical Analysis Plan and study protocol a time of publication
IPD-toegangscriteria voor delen
Curated by principle investigator according to contemporary law
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .